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The UK Food Standards Agency convened a group of expert scientists to review current research investigating the effect of dietary lipids
on vascular function. The workshop highlighted the need for intervention studies to be sufficiently powered for these measures and that
they should be corroborated with other, more validated, risk factors for CVD. Work presented at the workshop suggested a beneficial effect
of long-chain n-3 PUFA and a detrimental effect of trans fatty acids. The workshop also considered the importance of the choice of study
population in dietary intervention studies and that ‘at risk’ subgroups within the general population may be more appropriate than subjects
that are unrepresentatively healthy.
Vascular function: Dietary lipids: n-3 Polyunsaturated fatty acids: Fish oils: trans Fatty acids: Saturated fatty acids: Food
Standards Agency
On 3 March 2003, the UK Food Standards Agency (FSA)
convened a workshop on the use of measures of vascular
function in dietary intervention studies and the effect of
dietary lipids upon them. The results from recently com-
pleted studies (both FSA and non-FSA funded) were pre-
sented, and the workshop was chaired by Professor
Joseph Vita (Boston University). The aim of the workshop
was to determine where this work has taken us and where
further work should be concentrated, as well as acting as a
vehicle for dissemination. The research recommendations
will feed into the future direction of FSA-funded nutrition
research, and may also be of value in guiding other
funders.
The vascular endothelium is an active tissue and pos-
sesses numerous anti-atherogenic functions in a normal
healthy state. These include regulation of blood flow in
response to metabolic demands, inhibition of blood clotting
and prevention of inflammatory cell adhesion to and sub-
sequent migration through the endothelium. Endothelial
‘dysfunction’ can be considered to be present when the
properties of the endothelium, either in a basal state or
after stimulation, have altered in a way that is inappropriate
with regard to preservation of normal function. Endothelial
dysfunction is characterised by an alteration in phenotype,
including decreased bioavailability of NO, a shift in the
relative balance of pro- and anticoagulant factors, and
increased expression of pro-inflammatory molecules.
These changes may increase the risk for vasoconstriction,
thrombosis, vascular inflammation and plaque activation,
the processes that contribute to the development and clini-
cal expression of CVD. Impaired endothelium-dependent
vasodilation has emerged as a readily measurable endo-
thelial response that appears to correlate with a number
of diverse endothelial functions.
Evidence that endothelial dysfunction contributes to the
atherogenic process is provided by clinical studies showing
impaired vasodilator responses in patients with CVD
risk factors. These abnormalities are often present
before the development of clinically or angiographically
evident atherosclerosis. For example, classical risk factors
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including advancing age, dyslipidaemia, hypertension, dia-
betes mellitus and cigarette smoking have been associated
with impaired endothelium-dependent vasodilation. Simi-
larly, endothelial dysfunction has been reported in the set-
ting of novel risk factors, such as hyperhomocysteinaemia,
elevated lipoprotein(a) concentration, obesity, insulin
resistance and systemic inflammation and/or infection.
Patients with advanced atherosclerosis also display endo-
thelial dysfunction. Further evidence for the relevance of
endothelial dysfunction is provided by the observation
that diverse therapies proven to reduce cardiovascular
risk also have the ability to improve endothelial function.
Thus, lipid-lowering therapy, angiotensin-converting
enzyme inhibitors, smoking cessation and exercise all
improve endothelial function and reduce cardiovascular
risk. On the basis of these studies, endothelial function
has been proposed as a clinically useful barometer of the
combined impact of risk factors on vascular health (Vita
& Keaney, 2002).
The strongest evidence for the clinical importance of
endothelial function is provided by prospective studies
that demonstrate the prognostic value of endothelial dys-
function for CVD. This issue has been investigated in
patients with established atherosclerosis (Neunteufl et al.
2000; Scha¨chinger et al. 2000; Suwaidi et al. 2000; Heitzer
et al. 2001; Gokce et al. 2002, 2003; Halcox et al. 2002)
and in subjects with elevated CVD risk factors (Perticone
et al. 2001; Modena et al. 2002; Schindler et al. 2003).
To date, however, no study has specifically examined the
question of whether reversing endothelial dysfunction can
be equated with a reduction in cardiovascular risk. Such
information is critical before endothelial function can be
completely accepted as a true surrogate marker for cardio-
vascular risk.
Measurement of vascular function
A number of methods have been used to examine endo-
thelial function. Most examine endothelium-dependent
vasodilation. Vasodilator responses to endothelium-depen-
dent stimuli have been examined in the coronary circula-
tion using quantitative angiography, the forearm
microcirculation using venous occlusion plethysmography,
and the conduit brachial artery using high-resolution ultra-
sound (flow-mediated dilatation; FMD) (Vita, 2002). FMD
involves a series of ultrasonographic measurements of
blood vessel diameter and flow. A blood pressure cuff is
then placed around the arm and inflated to a suprasystolic
pressure for approximately 4 min. On release of the cuff
after 5 min, reactive hyperaemia is induced and shear
stress promotes endothelium-dependent vasorelaxation.
Alternatively, small vessel endothelial function can be
measured by using the skin circulation as a surrogate
marker of generalised microvascular endothelial function.
In this process, vasoactive chemicals (e.g. acetylcholine
(endothelium-dependent) and sodium nitroprusside (endo-
thelium-independent)) can be delivered transdermally to
the skin microvessels using a small electric current (ionto-
phoresis). The subsequent microvascular response can be
measured by laser Doppler imaging, which measures
perfusion in the top 1·0–1·5 mm of skin. Although the
prognostic value of small vessel endothelial function has
yet to be demonstrated, changes in the microcirculation
have been shown to parallel changes in the macrocircula-
tion (Ramsay et al. 2002).
Arterial ‘stiffness’ measures (based on measurements of
the material properties of the vessel wall or the capacitance
function of the vessel as a whole) can also be assessed:
pulse pressure, pulse wave analysis, pulse wave velocity,
digital volume pulse and pulse contour analyses. This is
a measure of the elasticity of the vessel (the relative
volume change for a given pressure increment) and
appears, in part, to depend on the vascular endothelium.
Measures of arterial ‘stiffness’ have the advantage of
being fast and simple and have been shown to have prog-
nostic value for cardiovascular events (Boutouyrie et al.
2002; London & Cohn, 2002; Safar et al. 2002).
Finally, circulating markers of endothelial function may
be assessed in blood. In subjects without known CVD, sol-
uble intracellular adhesion molecule-1 (Ridker et al. 1998)
and tissue plasminogen activator (Thogersen et al. 1998)
have been shown to predict future cardiovascular events.
In patients with known CVD, soluble intracellular adhesion
molecule-1 (Haim et al. 2002), von Willebrand factor
(Thompson et al. 1995; Wiman et al. 2000), tissue plasmi-
nogen activator (Thompson et al. 1995) and plasminogen
activator inhibitor-1 (Hamsten et al. 1987) are independent
predictors of future events. These studies are consistent
with studies suggesting that non-endothelium-derived mar-
kers of inflammation, such as C-reactive protein, identify
high-risk individuals (Pearson et al. 2003).
Most recently, endothelial progenitor cells have been
measured in blood and their function was shown to relate
to risk factors and endothelium-dependent vasodilation
(Hill et al. 2003). An important issue in this field is the
lack of uniform standards for measurement of endo-
thelium-dependent vasodilation or other aspects of endo-
thelial function, and the lack of a consensus in regard to the
best approach for specific types of study.
Dietary factors
The strength of evidence for dietary factors affecting endo-
thelial function differs for differing dietary constituents.
Replacement of a saturated fat-enriched diet with a high-
fat high-MUFA diet, but not a low-fat high-carbohydrate
diet, was shown to improve FMD in hypercholesterolaemic
patients (Fuentes et al. 2001); furthermore, in healthy sub-
jects, a high-fat high-MUFA diet was also shown to
decrease circulating markers of endothelial activation
(plasminogen activator inhibitor-1, von Willebrand factor
and tissue factor pathway inhibitor), whereas a low-fat
high-carbohydrate or high-fat high-saturated fat diet did
not (Perez-Jiminez et al. 1999). Other studies, however,
have shown no difference in either FMD (de Roos et al.
2001b) or arterial elasticity (Ashton et al. 2000) when com-
paring high-fat high-MUFA diets with low-fat high-carbo-
hydrate diets in healthy subjects.
High doses of fish oils (4–5 g EPA þ docosahexaenoic
acid (DHA)/d) have been shown to improve FMD in
hypercholesterolaemic subjects (Goodfellow et al. 2000),
forearm blood flow in healthy subjects (Chin et al. 1993)
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and endothelium-dependent vasodilator responses to intra-
coronary acetylcholine infusion in heart-transplant recipi-
ents (Fleischhauer et al. 1993). Mori et al. (2000)
demonstrated that DHA (4 g/d), but not EPA (4 g/d),
enhanced forearm blood flow.
High doses of folic acid (5–10 mg/d) have also been
shown to improve FMD in coronary-artery disease patients
(Title et al. 2000; Doshi et al. 2001) and smokers (O’Grady
et al. 2002), forearm blood flow, but not arterial elasticity,
in smokers (Mangoni et al. 2002), and volumetric coronary
blood flow in hyperhomocysteinaemic patients with coron-
ary artery disease (Willems et al. 2002). This effect was
shown to be independent of a plasma homocysteine-lower-
ing effect (Doshi et al. 2002). Lower doses of folic acid
(e.g. 0·4 mg/d), which are attainable through the diet and
result in maximal homocysteine reductions, have no
effect on FMD (Pullin et al. 2001; Hirsch et al. 2002).
Flavonoid-rich beverages have been demonstrated to
improve endothelial function with acute and long-term
intake of flavonoid-containing beverages including tea
(Duffy et al. 2001), grape juice (Stein et al. 1999) and
de-alcoholised red wine (Agewall et al. 2000).
The results from studies investigating the effect of high
doses of vitamin E (typically $590 mg a-tocopherol/d)
and vitamin C ($1 g/d) on endothelial function are equiv-
ocal (for review, see Duffy et al. 1999). Although one
study suggested that patients with multiple risk factors,
particularly cigarette smoking, derive benefit from vitamin
E supplementation (Heitzer et al. 1999), most other studies
have failed to show a beneficial effect in patients with cor-
onary artery disease or type 2 diabetes mellitus (Elliott
et al. 1995; Chowienczyk et al. 1998; Gazis et al. 1999;
Title et al. 2000). Studies of combinations of antioxidants,
typically vitamin C, vitamin E and b-carotene, have also
provided disappointing results (Gilligan et al. 1994;
MacKechnie et al. 2002). The findings with vitamin E
and combination antioxidant therapy are consistent with
large-scale clinical studies that demonstrated no benefit
of antioxidant treatment on CHD (GISSI-Prevenzione
Investigators, 1999; Yusuf et al. 2000; Heart Protection
Study Collaborative Group, 2002).
A large number of studies have demonstrated a beneficial
effect of acute, high-dose vitamin C (ascorbic acid) admin-
istration on endothelium-dependent vasodilation in patients
with CVD and other disease states (Duffy et al. 1999).
These studies provide insight into the pathophysiological
mechanisms of vascular dysfunction and support a role of
increased oxidative stress; however, the applicability of
these studies to chronic vitamin C treatment on clinical
endpoints remains uncertain.
It has been hypothesised that high-fat meals act as a trigger
for acute coronary syndromes in populations with estab-
lished atherosclerosis, by inducing a hypercoaguable and a
vasoconstrictor state (Anderson et al. 2001). Several studies
have demonstrated that high-fat meals, but not high-carbo-
hydrate low-fat meals, induce acute impairment of FMD
postprandially in healthy subjects (Plotnick et al. 1997,
2003; Vogel et al. 1997; Ong et al. 1999; Bae et al. 2001,
2003; Marchesi et al. 2000), diabetics (Fard et al. 2000)
and, to a greater extent, patients with CHD (Ling et al.
2002). This impairment was attenuated by supplementing
the test meal with either vitamins C (1–2 g) and E
(590 mg) (Plotnick et al. 1997, 2003; Katz et al. 2001;
Ling et al. 2002; Bae et al. 2003) or foods rich in these nutri-
ents (fruits and vegetables concentrate (Plotnick et al. 2003),
balsamic vinegar and salad (Vogel et al. 2000)). High-fat
meals have also been shown to postprandially impair the
coronary microcirculation (Hozumi et al. 2002), systemic
arterial compliance (Nestel et al. 2001) and the rheologic
response to L-arginine, which was attenuated by the addition
of vegetables rich in vitamins C and E to the test meal
(Esposito et al. 2003). Most studies also observed postpran-
dial impairment of vascular function following a high-fat
meal to be associated with postprandial hypertriacyglycero-
laemia; as background diet has also been shown to affect the
postprandial triacylglycerol response following a high-fat
meal (Roche et al. 1998; Wolever & Mehling, 2003) this
may also be a factor.
Not all studies, however, have demonstrated postpran-
dial impairment of FMD following a high-fat meal
(Djousse et al. 1999; Raitakari et al. 2000; Gokce et al.
2001; Sejda et al. 2002). The reason for this discrepancy
is unclear, and could be related to differences in the patient
population studied or in the specific type of fat consumed.
For example, Williams et al. (1999) demonstrated a meal
high in oxidised fat, but not uncooked fat, impaired
FMD; however, in a subsequent study no effect of heat
modified fat was observed (Williams et al. 2001).
Measure variability
Dr Margreet Olthof presented results on studies investi-
gating the variability in FMD of the brachial artery in
young healthy subjects. The variability of FMD is large
and this is important for the design of trials with FMD as
an end point. The within-subject CV of the FMD measured
off-line after images had been recorded on videotape
(B-mode) is 50 % (de Roos et al. 2003). In addition, the
within-subject variability of the FMD measured with the
wall-track method (M-mode) was determined: fourteen
healthy, non-smoking subjects (seven men, seven women;
age range 20–25 years) were measured on six occasions
after an overnight fast.
The main findings from the study were:
. the mean FMD was 7·8 (SD 2·6) % baseline diameter.
Within-subject CV of FMD measured with the wall-
track method was 46·4 %.
Thus, the within-subject variability of FMD measured
with the wall-track method was similar to that of the
B-mode. The consequences for the number of subjects
needed in intervention trials is as follows: to detect a 2 %
difference in FMD (power 0·80, a 0·05), thirty to fifty sub-
jects are needed in a crossover design, and sixty to one
hundred subjects per group in a parallel design. Variability
can be reduced by taking duplicate measurements. For B-
mode ultrasound, duplicate reading of the videotapes is
recommended, since the variation in reading of videotapes
is large (CV 34 %; de Roos et al. 2003). The variation of
50 % for single measurements was in accord with values
obtained by other workers present.
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Dietary modification of vascular function
Dr Bruce Griffin presented preliminary findings (BA
Griffin, MD Griffin, IR Davies, P Chowienczyk, GAA
Ferns, DJ Millward and TAB Sanders, unpublished
results) on indices of vascular function from an FSA-
funded project (the OPTILIP study) that attempts to ident-
ify the optimum proportions of a-linolenic and long-chain
n-3 PUFA in the UK diet with regard to cardiovascular
risk factors. Healthy middle-aged men and women (forty
men, thirty women, aged 45–65 years) were randomised
to diets: a control diet with an intake of n-6 and n-3
fatty acids similar to that in the UK diet; a diet enriched
with long-chain n-3 PUFA; a diet enriched with a similar
amount of a-linolenic acid; a diet enriched with long-
chain n-3 PUFA and a-linolenic acid; a diet with a
more moderate a-linolenic acid enrichment (the target
n-6:n-3 fatty acid ratios were 10:1, 3:1, 3:1, 3:1 and 5:1
respectively). The dietary intervention period was
6 months.
FMD was measured in the brachial artery at rest and
using a forearm occlusion cuff (5 min; endothelium-depen-
dent vasodilatation) and sublingual glycerol trinitrate
(300mg per tablet, 3 min; endothelium-independent vasodi-
latation) to induce reactive hyperaemia. Arterial diameters
were measured and averaged from four points in the two-
dimensional ultrasound image of the vessel wall at 30,
90 and 180 s post-cuff, and 3·5 and 5·0 min after the admin-
istration of glycerol trinitrate (30 and 90 s post-glycerol tri-
nitrate). FMD was assessed immediately before and after
6 months of dietary intervention.
These preliminary results suggest show no significant
dietary effects on maximal FMD or pulse wave velocity;
however, the duration of FMD may be less in subjects on
n-3 fatty acid-rich diets. The clinical relevance of this find-
ing, if confirmed, is unknown.
Dr Nicole de Roos presented the results of long-term
and postprandial studies of saturated and trans fatty
acids on vascular function. A high intake of trans fat
increases the risk of CHD and some investigators believe
that the effect of trans fatty acids is stronger than that of
saturated fatty acids (Ascherio et al. 1999). The changes
in serum cholesterol concentrations seen in metabolic
studies after feeding trans fatty acids for a few weeks
cannot fully explain the increased risk of CHD (Mensink
& Katan, 1992; Zock et al. 1995). Other effects, there-
fore, may contribute to the risk associated with high
intakes of trans fats. All studies were performed in
healthy volunteers between 18 and 70 years of age.
The long-term dietary controlled study was performed
in a crossover design with twenty-nine men and
women (de Roos et al. 2001a), the postprandial study
with twenty-one men (de Roos et al. 2002).
The main results were:
. replacement of 9·2 % energy from saturated fatty acids
by trans fatty acids significantly decreased serum HDL-
cholesterol after 4 weeks by 0·39 mmol/l (95 % CI 0·28,
0·50) and impaired FMD from 6·2 to 4·4 %, a decrease
of 1·8 %-points (95 % CI 0·4, 3·2);
. this long-term adverse effect of trans fatty acids was
not observed in the postprandial study: FMD after an
oral fat load of 1 g/kg bodyweight was 3·1 v. 2·6 %
before, with trans fatty acids and saturated fatty acids
having similar effects.
This work suggests, therefore, that only long-term repla-
cement of saturated fatty acids by trans fatty acids impairs
vascular function. This may explain why trans fatty acids
relate more strongly to risk of CVD than saturated fatty
acids. The absence of an impairment in postprandial
FMD was in contrast to some other, although not all,
studies described in the literature.
Dr David Muller presented results from projects funded
by the FSA, the Medical Research Council and the British
Heart Foundation: they investigated the effects of genetic
and other risk factors on the relationship between long-
chain n-3 PUFA, antioxidant status and vascular function
(Leeson et al. 2002a,b,c). Increased fish consumption
(resulting in increased n-3 PUFA consumption) and
increased vitamin E intake are associated with a decreased
risk of CVD, whereas a common variant of the endothelial
NO synthase gene (Glu298Asp) has been shown to
increase the risk of CVD (Shimasaki et al. 1998). These
factors alone or in combination with each other and other
known risk factors (e.g. smoking and blood lipids) have
been related to measures of vascular function in early
adulthood and thereby the development of CVD.
Endothelial function was assessed using FMD in 326
normal subjects aged 20–28 years. Arterial distensibility
was also measured. These measures of vascular function
were related to n-3 PUFA concentrations in plasma and
erythrocyte membranes, plasma vitamin E concentrations
and total antioxidant status, the genotype of the endothelial
NO synthase glutamate–aspartate polymorphism, cardio-
vascular risk factors and diet.
The principal findings were:
. FMD was significantly reduced in smokers (P,0·05)
and there was a significant positive relationship
between n-3 PUFA status and FMD in smokers
(P,0·01), which was not present in non-smokers
(Leeson et al. 2002c);
. there were significant positive relationships between
FMD and n-3 PUFA status in those subjects in the
top one-third for fasting glucose, insulin and triacylgly-
cerol levels with no relationships in those with lower
levels (Leeson et al. 2002c);
. neither plasma vitamin E concentrations (alone or
adjusted for lipid concentrations) nor total antioxidant
status were related to any of the measures of vascular
function (Leeson et al. 2002b);
. in the group as a whole, FMD was similar for the differ-
ent endothelial NO synthase genotypes (Leeson et al.
2002a);
. there were no significant differences in FMD between
smokers and non-smokers with the Glu/Glu genotype,
whereas in subjects with Glu/Asp and Asp/Asp geno-
types the smokers had a significantly reduced FMD
(P,0·01; Leeson et al. 2002a);
. there was a significant relationship between n-3 PUFA
status and FMD in Glu/Asp and Asp/Asp subjects
(P,0·05), but not in those with the Glu/Glu genotype
(Leeson et al. 2002a).
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These effects were seen with either DHA alone or
DHA þ EPA but not with EPA alone. The results show
particularly: (1) the positive relationship between n-3
PUFA status and FMD in smokers and the subjects in the
top one-third for fasting glucose, insulin and triacylgly-
cerol levels; (2) the positive relationship between n-3
PUFA status and FMD in the endothelial NO synthase
genotypes with an Asp allele, suggest the possibility of
prevention strategies with increased n-3 PUFA intake
targeted to specific groups at risk of CVD.
Professor Jill Belch presented results from two FSA-
funded projects investigating the effects of dietary lipids
on vascular function. In the first project (Khan et al.
2003), a total of 210 healthy subjects (men and women
aged 40–65 years, non-smokers) were randomised to one
of six groups (n 35) supplemented for 8 months with
either (g/d): placebo oil 10, olive oil 10, evening primrose
(Oenothera biennis) oil 5 þ placebo oil 5, soyabean oil
5 þ placebo oil 5; tuna oil 5 (0·30 g EPA, 1·35 g DHA) þ
placebo oil 5, evening primrose oil 5 þ tuna oil 5. The pla-
cebo oil comprised 250 g soyabean oil and 750 g fractio-
nated coconut oil/kg; this was designed to reflect the
average fatty acid composition of the Scottish diet.
Subjects were assessed for fatty acid status, biochemi-
cal and cellular markers of endothelial behaviour, haemo-
static function and endothelial cell function and vascular
tone, as determined by iontophoresis and laser Doppler
imaging.
The main results were:
. tuna oil improved endothelial-dependent vascular
responses; furthermore, there was a positive correlation
between endothelial-dependent vascular responses and
total plasma n-3 PUFA concentration;
. none of the other supplemented diets affected this
measure of endothelial cell function;
. platelet aggregation was decreased after tuna oil þ
evening primrose oil and after olive-oil supplemen-
tation, but increased after evening primrose-oil
supplementation.
These results suggests that fish-oil supplementation, at
levels attainable through the diet, enhances both endo-
thelial cell and platelet behaviour.
In the second study (JJF Belch, A Anderson, F Daly, J
Dick, M McClaren, F Khan, A Hill and K Barton, unpub-
lished results), 105 study healthy subjects (men and
women, non-smokers, age $40 years) were randomised,
following a 1-month run-in, to one of three dietary
groups (n 34): palmate, stearate or control. All subjects
were maintained on their habitual total, saturated and unsa-
turated fat intakes. The intervention period lasted 4
months. The palmate and stearate groups received 50–
60 % total saturated fat intake (6–10 % total dietary
energy) exchanged with either palmitic or stearic acid
respectively. Professor Annie Anderson presented details
of how this was achieved using margarines and biscuits
of the appropriate saturated fat composition provided by
Unilever (Vlaardingen, The Netherlands). Subjects were
assessed for saturated fatty acid status, endothelial cell
function and vascular tone (using iontophoresis and laser
Doppler imaging), arterial compliance (pulse wave
augmentation measured at the radial artery using applana-
tion tonometry) and haemostatic function.
The main results were:
. no changes in any of the measures of vascular function
were observed either before or after any of the dietary
interventions;
. analysis of the biochemical and cellular markers
showed no significant changes between the experimen-
tal groups and the control group. Analysis pre- and
post-intervention, however, showed no significant
changes in the control group, but the exchange that
increased stearic acid seemed to produce what might
be considered as beneficial changes, whereas the palmi-
tic acid exchange did not. In the stearic group platelet
NO production increased, P-selectin, E-selectin and
fibrinogen levels fell, and in the palmitic acid group
prothrombin time increased;
. in the palmitic acid group the proportion of oleic acid
was decreased in the esterified forms of fatty acids pre-
sent in plasma relative to the stearic acid and control
groups.
In conclusion, therefore, in the first of these studies vaso-
dilator changes were achieved in endothelial cell function
with tuna-oil supplementation. In the second study, stearic
acid appears to have some advantages over palmitic acid in
terms of potential CV effects, but neither affected vascular
function.
Professor Philip Calder presented results from an FSA-
funded project investigating the association of n-3 PUFA
with stability of advanced atherosclerotic plaques (Thies
et al. 2003). Patients awaiting carotid endarterectomy
were randomly assigned to consume placebo, sunflower-
oil or fish-oil capsules until surgery, when the atherosclero-
tic plaque was removed (n . 59 per treatment group).
Patients in the fish-oil group consumed an extra 1·4 g
EPA and DHA/d. The fatty acid compositions of LDL
and carotid plaque were determined. Plaques were classi-
fied morphologically. The presence of T lymphocytes and
macrophages in the plaques was determined by immuno-
histochemistry. The mean duration of supplementation
was 50 (range 7–189) d and did not differ between the
groups.
The main results were:
. plasma triacylglycerol concentration was significantly
decreased (mean decrease 28 %) in patients receiving
fish oil;
. the proportions of EPA and DHA increased signifi-
cantly in LDL-lipid fractions in patients receiving fish
oil. The proportions of EPA and DHA were higher in
carotid plaque phospholipids, cholesteryl esters and
triacylglycerols in patients receiving fish oil compared
with patients in the placebo group;
. in the fish-oil group, fewer plaques had thin fibrous
caps and signs of inflammation and more plaques had
thick fibrous caps and fewer signs of inflammation,
compared with the other two groups;
. the number of macrophages in the plaques from
patients receiving fish oil was lower than in the other
two groups.
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This study shows that advanced atherosclerotic plaques
are dynamic and readily incorporate n-3 PUFA. Incorpor-
ation of n-3 PUFA into carotid plaques is associated with
a reduced number of macrophages and fewer signs of
inflammation. These observations suggest that n-3 PUFA
induce changes that may increase the stability of athero-
sclerotic plaques. If this is so, it represents a novel mech-
anism by which fish oil might prevent non-fatal and fatal
cardiovascular events (for discussion, see Thies et al.
2003). The mechanism by which fish oil decreases the
number of macrophages in plaques is not clear; it may
involve decreased infiltration, increased loss (increased
movement out of plaques or increased apoptosis) or a com-
bination of such effects. The study did not investigate the
activation state of the macrophages or the presence of
inflammatory mediators within the plaques. These will be
examined in a new study.
Professor Robert Grimble presented results from an
extension of the previous FSA project to determine whether
genetic variation in cytokine genes influences the effect of
PUFA on atherosclerotic plaques (RF Grimble, WM
Howell, PC Calder, CP Sheraman, P Gallagher, K Rekasem
and F Thies, unpublished results). Inflammation plays a
pivotal role in the development and stability of athero-
sclerotic plaques. Cytokines, key mediators of the inflam-
matory process, have been demonstrated to be present in
atherosclerotic plaques (Ross, 1999). Individuals can be
classed as habitually high-, medium-, or low-producers of
certain cytokines (Jacob et al. 1990). Single nucleotide
polymorphisms in cytokine genes, usually in the promoter
region, result in altered levels of cytokine production, e.g.
TNF-a. Single nucleotide polymorphisms in pro-inflamma-
tory cytokine genes have been linked with increased mor-
tality during infection and after surgery (McGuire et al.
1994; Stuber et al. 1996) and with increased susceptibility
to inflammatory disease (Schaaf et al. 2001). The ability
of fish oil to exert an anti-inflammatory effect in healthy
subjects, by suppression of TNF production, was influenced
by the pre-supplementation level of cytokine production,
and by single nucleotide polymorphisms at þ252 in the
TNF-b gene (Grimble et al. 2002).
Preliminary studies indicate that:
. TNFB22 variant of the TNF-b single nucleotide poly-
morphism may influence the soft lipid content of
plaques;
. plaque characteristics, assessed according to the modi-
fied American Heart Association score, indicate that
fish-oil supplementation results in plaques with a
lower score in subjects possessing the TNF2 allele of
the single nucleotide polymorphism in the TNF gene
than patients homozygous for the TNF1 allele.
Thus, genotypes associated with a raised inflammatory
status may be influenced to a greater extent by PUFA sup-
plementation than those associated with a lower status. It
should be noted, however, that due to the varying lengths
of PUFA supplementation time and the absence of any
effect on clinical end points, the results should be treated
with some caution.
Currently, Biotechnology and Biological Sciences
Research Council-funded studies are investigating the
genomic nature of differing sensitivities of cytokine pro-
duction to the anti-inflammatory influence of fish oil and
vitamin E. Further work on gene nutrient influences on
atherosclerosis requires clear demonstrations of clinical
benefits resulting from nutritional intervention.
Discussion
Endothelial function appears to reflect the integrated
effects of risk factors on the vasculature, and the develop-
ment of endothelial dysfunction is an early event in the
atherogenic process. Measures of endothelial function
may provide a useful non-invasive methodology for asses-
sing a clinically relevant surrogate end point; however,
there is much methodological and physiological variability
and this requires that studies are sufficiently powered in
terms of sample size. Further, these issues make a cross-
over study design particularly useful.
Whether effecting a change in endothelial function
results in a corresponding change in CVD risk remains to
be determined. Measures of endothelial function, therefore,
should be corroborated with other, more validated, risk fac-
tors for CVD, both conventional (fasting lipids, blood
pressure, glucose concentration), and novel (high-sensi-
tivity C-reactive protein, soluble intercellular adhesion
molecule-1, von Willebrand factor, tissue plasminogen
activator, plasminogen activator inhibitor-1), and measures
of insulin sensitivity. As different study populations may
display different risk factors, the choice of corroborating
measures may depend on the specific study population.
Work presented at the workshop showed that in healthy
subjects moderate fish-oil supplementation, at levels attain-
able through the diet, had a beneficial effect on endothelial
function. Other ongoing FSA studies also address this issue
and confirmation of an effect of dietary levels of n-3 PUFA
on endothelial function will be important. In subjects at
risk of CVD, higher circulating levels of DHA and EPA
were associated with improved endothelial function. In
patients awaiting carotid endartectomy, moderate fish-oil
supplementation appeared to stabilise advanced athero-
sclerotic plaques making them less likely to rupture. Over-
all, these studies lend further support for population dietary
recommendations to increase intake of oily fish. Other
work presented showed that replacement of dietary satu-
rated fatty acids with trans fatty acids impairs endothelial
function and further supports population dietary re-
commendations to reduce trans fatty acid intake.
Another issue that was highlighted at the workshop is the
choice of study population. The remit of FSA-funded
research is not to study disease per se, but the impact of
diet on the prevention of disease. The extrapolation of
data from a disease population to a ‘normal’ population
is difficult; however, if too many conditions of ‘normality’
are stipulated in the study inclusion criteria (e.g. blood
pressure, BMI, plasma lipids) the study population can be
unrepresentatively healthy: almost 30 % of the English
population have been diagnosed with some form of CVD
(Department of Health, 1999). In addition, it is unlikely
that relatively short-term interventions with modest
changes in dietary intake can adequately mimic the effects
of a lifetime exposure in individuals who are ‘healthy’.
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Study populations exhibiting one or more risk factors for
CVD, therefore, may be a more appropriate model and
would also highlight vulnerable groups within the general
population.
Recommendations
. Measures of endothelial function may provide a useful
non-invasive methodology for assessing a clinically rel-
evant surrogate endpoint, but at present such measures
should be used in the context of studies that use other
more traditional risk factors and other surrogate end
points for CVD.
. For dietary intervention studies it is important to pro-
vide enough statistical power to account for both
measure and physiological variation.
. The choice of study population in dietary intervention
studies is important: ‘at risk’ subgroups within the gen-
eral population may be more appropriate, e.g. as defined
by CVD risk factors, genotype or lifestyle factors.
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